Hansa Biopharma AB appointed Renée Aguiar-Lucander as Chief Executive Officer (CEO), effective immediately. Søren Tulstrup will be stepping down from his position as CEO by mutual agreement after seven years with the company.

“On behalf of the Board of Directors, I would like to extend our gratitude to Søren for his leadership and significant contribution to the company during his tenure,” said Peter Nicklin, Chairman of the Board, Hansa Biopharma. “With the appointment of Renée as CEO, Hansa is entering a new phase of growth and development. Renée brings extensive experience in both the biopharmaceutical and financial sectors, and her proven leadership will be instrumental in advancing the Company’s strategic positioning.”

Aguiar-Lucander served for seven years as CEO of Calliditas Therapeutics AB, where she successfully led the company through a dual listing on NASDAQ in Sweden and the U.S. 

During her tenure, the company successfully launched and commercialized the first ever approved drug for immunoglobulin A (IgA) nephropathy in the U.S. Before that, Aguiar-Lucander had a long and successful career in the healthcare investment sector, holding senior roles in funds such as Omega Funds and 3i Group.

Aguiar-Lucander, commented, I “hope to bring relevant perspectives from my previous roles, both with regards to capital raising and management, as well as insights regarding regulatory, commercial preparation, and launch dynamics. I look forward to working with the team and Board to ensure Hansa’s future success.”